Back to top
more

Xilio Therapeutics (XLO)

(Delayed Data from NSDQ)

$1.12 USD

1.12
113,132

+0.06 (5.66%)

Updated Jun 11, 2024 04:00 PM ET

After-Market: $1.12 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for XLO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Xilio Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 45 120 198 19 -99,999
Receivables 0 0 0 0 NA
Notes Receivable 0 0 0 0 NA
Inventories 0 0 0 0 NA
Other Current Assets 3 4 4 1 NA
Total Current Assets 48 125 203 21 NA
Net Property & Equipment 6 7 8 7 NA
Investments & Advances 0 0 0 0 NA
Other Non-Current Assets 0 0 0 0 NA
Deferred Charges 0 0 0 0 NA
Intangibles 0 0 0 0 NA
Deposits & Other Assets 2 2 2 2 NA
Total Assets 61 139 218 36 NA
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 3 7 0 2 NA
Accounts Payable 1 3 3 5 NA
Current Portion Long-Term Debt 0 0 0 0 NA
Current Portion Capital Leases 0 0 0 0 NA
Accrued Expenses 11 10 9 14 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 0 0 0 0 NA
Total Current Liabilities 16 21 13 22 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 0 0 0 0 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 0 3 10 7 NA
Non-Current Capital Leases 0 0 0 0 NA
Other Non-Current Liabilities 0 0 0 1 NA
Minority Interest (Liabilities) 0 0 0 0 NA
Total Liabilities 24 34 33 42 NA
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 78 NA
Common Stock (Par) 0 0 0 0 NA
Capital Surplus 362 355 346 2 NA
Retained Earnings -326 -249 -161 -85 NA
Other Equity 0 0 0 0 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity 37 106 185 -5 NA
Total Liabilities & Shareholder's Equity 61 139 218 36 NA
Total Common Equity 37 106 185 -83 0
Shares Outstanding 27.50 27.40 26.60 NA NA
Book Value Per Share 1.34 3.86 6.97 0.00 0.00

Fiscal Year End for Xilio Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 34 45 60 75 93
Receivables 30 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 5 3 5 3 4
Total Current Assets 69 48 64 78 97
Net Property & Equipment 6 6 6 7 7
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 3 2 2 2 2
Total Assets 83 61 78 92 112
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 3 5 7 7
Accounts Payable 1 1 1 1 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 8 11 9 7 6
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 22 0 0 0 0
Total Current Liabilities 32 16 17 16 16
Mortgages 0 0 0 0 0
Deferred Taxes/Income 17 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 2
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 57 24 25 25 27
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 368 362 360 358 357
Retained Earnings -343 -326 -308 -291 -272
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 26 37 53 67 85
Total Liabilities & Shareholder's Equity 83 61 78 92 112
Total Common Equity 26 37 53 67 85
Shares Outstanding 36.90 27.50 27.50 27.40 27.40
Book Value Per Share 0.70 1.34 1.91 2.46 3.09